PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15721872-7	2005	RESULTS: In 9,11-dideoxy-11alpha,9alpha-epoxy-methanoprostaglandin F(2alpha) (U46619)-precontracted endothelium-intact rings, urocortin induced concentration-dependent relaxations with pD(2) of 8.69+/-0.11 and this effect was markedly reduced in endothelium-denuded rings.	9,11-dideoxy-11alpha	12-32	urocortin	Homo sapiens	126-135	
15721872-7	2005	RESULTS: In 9,11-dideoxy-11alpha,9alpha-epoxy-methanoprostaglandin F(2alpha) (U46619)-precontracted endothelium-intact rings, urocortin induced concentration-dependent relaxations with pD(2) of 8.69+/-0.11 and this effect was markedly reduced in endothelium-denuded rings.	9alpha-epoxy-methanoprostaglandin f	33-68	urocortin	Homo sapiens	126-135	
15721872-8	2005	Relaxations to urocortin in endothelium-intact rings were attenuated to the same extent after treatment with N(G)-nitro-l-arginine (l-NNA) and 1H-[1,2,4]oxadizolo[4,3-a]quinoxalin-1-one (ODQ).	Nitroarginine	109-130	urocortin	Homo sapiens	15-24	
15721872-8	2005	Relaxations to urocortin in endothelium-intact rings were attenuated to the same extent after treatment with N(G)-nitro-l-arginine (l-NNA) and 1H-[1,2,4]oxadizolo[4,3-a]quinoxalin-1-one (ODQ).	Nitroarginine	132-137	urocortin	Homo sapiens	15-24	
15721872-8	2005	Relaxations to urocortin in endothelium-intact rings were attenuated to the same extent after treatment with N(G)-nitro-l-arginine (l-NNA) and 1H-[1,2,4]oxadizolo[4,3-a]quinoxalin-1-one (ODQ).	1h-[1,2,4]oxadizolo[4,3-a]quinoxalin-1-one	143-185	urocortin	Homo sapiens	15-24	
15721872-8	2005	Relaxations to urocortin in endothelium-intact rings were attenuated to the same extent after treatment with N(G)-nitro-l-arginine (l-NNA) and 1H-[1,2,4]oxadizolo[4,3-a]quinoxalin-1-one (ODQ).	1H-(1,2,3)oxadiazolo(4,4-a)quinoxalin-1-one	187-190	urocortin	Homo sapiens	15-24	
15721872-9	2005	Urocortin-induced relaxations were also inhibited by treatment with putative K(+) channel blockers, such as tetraethylammonium (TEA(+)), charybdotoxin (CTX), and iberiotoxin (IBX).	Tetraethylammonium	108-126	urocortin	Homo sapiens	0-9	
15721872-9	2005	Urocortin-induced relaxations were also inhibited by treatment with putative K(+) channel blockers, such as tetraethylammonium (TEA(+)), charybdotoxin (CTX), and iberiotoxin (IBX).	Charybdotoxin	137-150	urocortin	Homo sapiens	0-9	
15721872-9	2005	Urocortin-induced relaxations were also inhibited by treatment with putative K(+) channel blockers, such as tetraethylammonium (TEA(+)), charybdotoxin (CTX), and iberiotoxin (IBX).	iberiotoxin	162-173	urocortin	Homo sapiens	0-9	
15721872-9	2005	Urocortin-induced relaxations were also inhibited by treatment with putative K(+) channel blockers, such as tetraethylammonium (TEA(+)), charybdotoxin (CTX), and iberiotoxin (IBX).	iberiotoxin	175-178	urocortin	Homo sapiens	0-9	
15721872-10	2005	In endothelium-denuded rings, treatment with TEA(+), CTX, or IBX attenuated relaxation to urocortin as well as sodium nitroprusside (SNP).	iberiotoxin	61-64	urocortin	Homo sapiens	90-99	
15721872-13	2005	The endothelium-dependent component primarily involves the release of endothelial nitric oxide (NO) that in turn stimulates Ca(2+)-activated K(+) channels in vascular smooth muscle via cyclic GMP-dependent mechanisms.	Nitric Oxide	82-94	5'-nucleotidase, cytosolic II	Homo sapiens	192-195